

This Document can be made available
in alternative formats upon request

State of Minnesota
HOUSE OF REPRESENTATIVES

EIGHTY-NINTH SESSION

H. F. No. 3333

03/17/2016 Authored by Barrett
The bill was read for the first time and referred to the Committee on Public Safety and Crime Prevention Policy and Finance
03/31/2016 Adoption of Report: Placed on the General Register
Read Second Time
05/16/2016 Calendar for the Day
Read Third Time
Passed by the House and transmitted to the Senate
05/22/2016 Passed by the Senate and returned to the House
05/24/2016 Presented to Governor
05/31/2016 Governor Approval

1.1 A bill for an act
1.2 relating to health; modifying the schedules of controlled substances; amending
1.3 Minnesota Statutes 2015 Supplement, section 152.02, subdivisions 2, 5.

1.4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 Section 1. Minnesota Statutes 2015 Supplement, section 152.02, subdivision 2, is
1.6 amended to read:

1.7 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this
1.8 subdivision.

1.9 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of
1.10 the following substances, including their analogs, isomers, esters, ethers, salts, and salts
1.11 of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
1.12 ethers, and salts is possible:

1.13 (1) acetylmethadol;

1.14 (2) allylprodine;

1.15 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
1.16 levomethadyl acetate);

1.17 (4) alphameprodine;

1.18 (5) alphasmethadol;

1.19 (6) alpha-methylfentanyl benzethidine;

1.20 (7) betacetylmethadol;

1.21 (8) betameprodine;

1.22 (9) betamethadol;

1.23 (10) betaprodine;

1.24 (11) clonitazene;

- 2.1 (12) dextromoramide;
- 2.2 (13) diampromide;
- 2.3 (14) diethylambutene;
- 2.4 (15) difenoxin;
- 2.5 (16) dimenoxadol;
- 2.6 (17) dimepheptanol;
- 2.7 (18) dimethylambutene;
- 2.8 (19) dioxaphetyl butyrate;
- 2.9 (20) dipipanone;
- 2.10 (21) ethylmethylthiambutene;
- 2.11 (22) etonitazene;
- 2.12 (23) etoxeridine;
- 2.13 (24) furethidine;
- 2.14 (25) hydroxypethidine;
- 2.15 (26) ketobemidone;
- 2.16 (27) levomoramide;
- 2.17 (28) levophenacylmorphan;
- 2.18 (29) 3-methylfentanyl;
- 2.19 (30) acetyl-alpha-methylfentanyl;
- 2.20 (31) alpha-methylthiofentanyl;
- 2.21 (32) benzylfentanyl beta-hydroxyfentanyl;
- 2.22 (33) beta-hydroxy-3-methylfentanyl;
- 2.23 (34) 3-methylthiofentanyl;
- 2.24 (35) thenylfentanyl;
- 2.25 (36) thiofentanyl;
- 2.26 (37) para-fluorofentanyl;
- 2.27 (38) morpheridine;
- 2.28 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 2.29 (40) noracymethadol;
- 2.30 (41) norlevorphanol;
- 2.31 (42) normethadone;
- 2.32 (43) norpipanone;
- 2.33 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 2.34 (45) phenadoxone;
- 2.35 (46) phenampromide;
- 2.36 (47) phenomorphan;

- 3.1 (48) phenoperidine;
- 3.2 (49) piritramide;
- 3.3 (50) proheptazine;
- 3.4 (51) properidine;
- 3.5 (52) propiram;
- 3.6 (53) racemoramide;
- 3.7 (54) tilidine;
- 3.8 (55) trimeperidine;
- 3.9 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl).

3.10 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
3.11 and salts of isomers, unless specifically excepted or unless listed in another schedule,
3.12 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

- 3.13 (1) acetorphine;
- 3.14 (2) acetyldihydrocodeine;
- 3.15 (3) benzylmorphine;
- 3.16 (4) codeine methylbromide;
- 3.17 (5) codeine-n-oxide;
- 3.18 (6) cyprenorphine;
- 3.19 (7) desomorphine;
- 3.20 (8) dihydromorphine;
- 3.21 (9) drotebanol;
- 3.22 (10) etorphine;
- 3.23 (11) heroin;
- 3.24 (12) hydromorphenol;
- 3.25 (13) methyl-desorphine;
- 3.26 (14) methyldihydromorphine;
- 3.27 (15) morphine methylbromide;
- 3.28 (16) morphine methylsulfonate;
- 3.29 (17) morphine-n-oxide;
- 3.30 (18) myrophine;
- 3.31 (19) nicocodeine;
- 3.32 (20) nicomorphine;
- 3.33 (21) normorphine;
- 3.34 (22) pholcodine;
- 3.35 (23) thebacon.

(d) Hallucinogens. Any material, compound, mixture or preparation which contains any quantity of the following substances, their analogs, salts, isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

- (1) methylenedioxy amphetamine;
- (2) methylenedioxymethamphetamine;
- (3) methylenedioxy-N-ethylamphetamine (MDEA);
- (4) n-hydroxy-methylenedioxyamphetamine;
- (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
- (6) 2,5-dimethoxyamphetamine (2,5-DMA);
- (7) 4-methoxyamphetamine;
- (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
- (9) alpha-ethyltryptamine;
- (10) bufotenine;
- (11) diethyltryptamine;
- (12) dimethyltryptamine;
- (13) 3,4,5-trimethoxyamphetamine;
- (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- (15) ibogaine;
- (16) lysergic acid diethylamide (LSD);
- (17) mescaline;
- (18) parahexyl;
- (19) N-ethyl-3-piperidyl benzilate;
- (20) N-methyl-3-piperidyl benzilate;
- (21) psilocybin;
- (22) psilocyn;
- (23) tenocyclidine (TPCP or TCP);
- (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
- (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
- (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);

- 5.1 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- 5.2 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
- 5.3 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 5.4 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
- 5.5 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 5.6 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 5.7 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
- 5.8 (2-CB-FLY);
- 5.9 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 5.10 (40) alpha-methyltryptamine (AMT);
- 5.11 (41) N,N-diisopropyltryptamine (DiPT);
- 5.12 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 5.13 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 5.14 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
- 5.15 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 5.16 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 5.17 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 5.18 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 5.19 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
- 5.20 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 5.21 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
- 5.22 (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
- 5.23 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
- 5.24 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 5.25 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 5.26 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 5.27 (57) methoxetamine (MXE);
- 5.28 (58) 5-iodo-2-aminoindane (5-IAI);
- 5.29 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 5.30 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
- 5.31 (25B-NBOMe);
- 5.32 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
- 5.33 (25C-NBOMe);
- 5.34 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
- 5.35 (25I-NBOMe);
- 5.36 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
(65) N,N-Dipropyltryptamine (DPT);
(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, ethketamine, NENK); and
(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA).

(e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian Church, and members of the American Indian Church are exempt from registration. Any person who manufactures peyote for or distributes peyote to the American Indian Church, however, is required to obtain federal registration annually and to comply with all other requirements of law.

(f) Central nervous system depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

(1) mecloqualone;
(2) methaqualone;
(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
(4) flunitrazepam; and
(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone
(2-MeO-2-deschloroketamine, methoxyketamine).

(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

(1) aminorex;
(2) cathinone;
(3) fenethylamine;
(4) methcathinone;

- 7.1 (5) methylaminorex;
 7.2 (6) N,N-dimethylamphetamine;
 7.3 (7) N-benzylpiperazine (BZP);
 7.4 (8) methylmethcathinone (mephedrone);
 7.5 (9) 3,4-methylenedioxy-N-methylcathinone (methydone);
 7.6 (10) methoxymethcathinone (methedrone);
 7.7 (11) methylenedioxypyrovalerone (MDPV);
 7.8 (12) 3-fluoro-N-methylcathinone (3-FMC);
 7.9 (13) methylethcathinone (MEC);
 7.10 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
 7.11 (15) dimethylmethcathinone (DMMC);
 7.12 (16) fluoroamphetamine;
 7.13 (17) fluoromethamphetamine;
 7.14 (18) α -methylaminobutyrophenone (MABP or buphedrone);
 7.15 (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
 7.16 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
 7.17 (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone
 7.18 or naphyrone);
 7.19 (22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
 7.20 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
 7.21 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
 7.22 (25) 4-methyl-N-ethylcathinone (4-MEC);
 7.23 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
 7.24 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
 7.25 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentydone);
 7.26 (29) 4-fluoro-N-methylcathinone (4-FMC);
 7.27 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
 7.28 (31) alpha-pyrrolidinobutiophenone (α -PBP);
 7.29 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
 7.30 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
 7.31 ~~(33)~~ (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); and
 7.32 ~~(34)~~ (35) any other substance, except bupropion or compounds listed under a
 7.33 different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
 7.34 at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
 7.35 the compound is further modified in any of the following ways:

(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii) by substitution at the 3-position with an acyclic alkyl substituent;

(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or

(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically excepted or unless listed in another schedule, any natural or synthetic material, compound, mixture, or preparation that contains any quantity of the following substances, their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible:

(1) marijuana;

(2) tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis*, synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant, or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including, but not limited to, 1 *cis* or *trans* tetrahydrocannabinol, 6 *cis* or *trans* tetrahydrocannabinol, and 3,4 *cis* or *trans* tetrahydrocannabinol;

(3) synthetic cannabinoids, including the following substances:

(i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylindoles include, but are not limited to:

(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

(ii) Naphthylmethyloindoles, which are any compounds containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethyloindoles include, but are not limited to:

(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);

(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).

(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).

(iv) Naphthylmethyloindenes, which are any compounds containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethyloindenes include, but are not limited to, E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).

(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of phenylacetylindoles include, but are not limited to:

(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);

(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);

(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

(vi) Cyclohexylphenols, which are compounds containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not

10.1 substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
10.2 but are not limited to:

10.3 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);

10.4 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol

10.5 (Cannabicyclohexanol or CP 47,497 C8 homologue);

10.6 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
10.7 -phenol (CP 55,940).

10.8 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
10.9 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
10.10 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
10.11 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
10.12 any extent and whether or not substituted in the phenyl ring to any extent. Examples of
10.13 benzoylindoles include, but are not limited to:

10.14 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

10.15 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

10.16 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
10.17 (WIN 48,098 or Pravadoline).

10.18 (viii) Others specifically named:

10.19 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.20 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

10.21 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.22 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

10.23 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
10.24 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

10.25 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

10.26 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
10.27 (XLR-11);

10.28 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
10.29 (AKB-48(APINACA));

10.30 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
10.31 (5-Fluoro-AKB-48);

10.32 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

10.33 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
10.34 PB-22);

10.35 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-
10.36 3-carboxamide (AB-PINACA);

- 11.1 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
 11.2 1H-indazole-3-carboxamide (AB-FUBINACA);
- 11.3 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
 11.4 indazole-3-carboxamide(AB-CHMINACA);
- 11.5 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-
 11.6 methylbutanoate (5-fluoro-AMB);
- 11.7 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 11.8 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
 11.9 (FUBIMINA);
- 11.10 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
 11.11 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 11.12 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
 11.13 -1H-indole-3-carboxamide (5-fluoro-ABICA);
- 11.14 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
 11.15 -1H-indole-3-carboxamide;
- 11.16 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
 11.17 -1H-indazole-3-carboxamide; and
- 11.18 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)
 11.19 -3,3-dimethylbutanoate;
- 11.20 (U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
 11.21 H-indazole-3-carboxamide (MAB-CHMINACA);
- 11.22 (V)
 11.23 N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
 11.24 (ADB-PINACA);
- 11.25 (W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
- 11.26 (X)
 11.27 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide.
 11.28 (APP-CHMINACA); and
- 11.29 (Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22).
- 11.30 (i) A controlled substance analog, to the extent that it is implicitly or explicitly
 11.31 intended for human consumption.

11.32 Sec. 2. Minnesota Statutes 2015 Supplement, section 152.02, subdivision 5, is
 11.33 amended to read:

11.34 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this
 11.35 subdivision.

12.1 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
12.2 any material, compound, mixture, or preparation containing any of the following narcotic
12.3 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
12.4 as follows:

12.5 (1) not more than one milligram of difenoxin and not less than 25 micrograms of
12.6 atropine sulfate per dosage unit;

12.7 (2) dextropropoxyphene (Darvon and Darvocet);

12.8 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical
12.9 and geometric isomers, and salts of these isomers (including tramadol); and

12.10 (4) eluxadoline.

12.11 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
12.12 any material, compound, mixture, or preparation containing any quantity of the following
12.13 substances, including its salts, isomers, and salts of isomers whenever the existence of the
12.14 salts, isomers, and salts of isomers is possible:

12.15 (1) alfaxalone (5 α -pregnan-3 α -ol-11,20-dione);

12.16 (2) alprazolam;

12.17 (3) barbital;

12.18 (4) bromazepam;

12.19 (5) camazepam;

12.20 (6) carisoprodol;

12.21 (7) chloral betaine;

12.22 (8) chloral hydrate;

12.23 (9) chlordiazepoxide;

12.24 (10) clobazam;

12.25 (11) clonazepam;

12.26 (12) clorazepate;

12.27 (13) clotiazepam;

12.28 (14) cloxazolam;

12.29 (15) delorazepam;

12.30 (16) diazepam;

12.31 (17) dichloralphenazone;

12.32 (18) estazolam;

12.33 (19) ethchlorvynol;

12.34 (20) ethinamate;

12.35 (21) ethyl loflazepate;

12.36 (22) fludiazepam;

- 13.1 (23) flurazepam;
- 13.2 (24) fospropofol;
- 13.3 (25) halazepam;
- 13.4 (26) haloxazolam;
- 13.5 (27) ketazolam;
- 13.6 (28) lorazepam;
- 13.7 (29) lorazepam;
- 13.8 (30) lormetazepam mebutamate;
- 13.9 (31) medazepam;
- 13.10 (32) meprobamate;
- 13.11 (33) methohexital;
- 13.12 (34) methylphenobarbital;
- 13.13 (35) midazolam;
- 13.14 (36) nimetazepam;
- 13.15 (37) nitrazepam;
- 13.16 (38) nordiazepam;
- 13.17 (39) oxazepam;
- 13.18 (40) oxazolam;
- 13.19 (41) paraldehyde;
- 13.20 (42) petrichloral;
- 13.21 (43) phenobarbital;
- 13.22 (44) pinazepam;
- 13.23 (45) prazepam;
- 13.24 (46) quazepam;
- 13.25 (47) suvorexant;
- 13.26 (48) temazepam;
- 13.27 (49) tetrazepam;
- 13.28 (50) triazolam;
- 13.29 (51) zaleplon;
- 13.30 (52) zolpidem;
- 13.31 (53) zopiclone.

13.32 (d) Any material, compound, mixture, or preparation which contains any quantity of
13.33 the following substance including its salts, isomers, and salts of such isomers, whenever
13.34 the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.

13.35 (e) Stimulants. Unless specifically excepted or unless listed in another schedule,
13.36 any material, compound, mixture, or preparation which contains any quantity of the

- 14.1 following substances having a stimulant effect on the central nervous system, including its
14.2 salts, isomers, and salts of isomers:
- 14.3 (1) cathine (norpseudoephedrine);
 - 14.4 (2) diethylpropion;
 - 14.5 (3) fencamfamine;
 - 14.6 (4) fenproporex;
 - 14.7 (5) mazindol;
 - 14.8 (6) mefenorex;
 - 14.9 (7) modafinil;
 - 14.10 (8) pemoline (including organometallic complexes and chelates thereof);
 - 14.11 (9) phentermine;
 - 14.12 (10) pipradol;
 - 14.13 (11) sibutramine;
 - 14.14 (12) SPA (1-dimethylamino-1,2-diphenylethane).
 - 14.15 (f) lorcaserin.